Customize your JAMA Network experience by selecting one or more topics from the list below.
Author Affiliations: Dr Bauchner (email@example.com) is Editor in Chief, Dr Fontanarosa is Executive Editor, and Dr Golub is Deputy Editor, JAMA.
In this issue of JAMA, Lamas and colleagues1 report the results of the Trial to Assess Chelation Therapy (TACT). In this multicenter clinical trial, 1708 patients with previous myocardial infarction (MI) were randomized to receive 40 infusions of chelation solution vs placebo. After a median follow-up of 55 months, the primary end point (a composite of total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina) occurred in 222 patients (26%) in the chelation group and in 261 patients (30%) in the placebo group, with the major between-group difference involving fewer coronary revascularization procedures in the chelation group (15%) than in the placebo group (18%). The authors conclude that although chelation therapy modestly reduced the risk of a composite of adverse cardiovascular outcomes, the results “are not sufficient to support the routine use of chelation therapy for treatment of patients who have had an MI.”
Bauchner H, Fontanarosa PB, Golub RM. Evaluation of the Trial to Assess Chelation Therapy (TACT): The Scientific Process, Peer Review, and Editorial Scrutiny. JAMA. 2013;309(12):1291–1292. doi:10.1001/jama.2013.2761
Create a personal account or sign in to: